Mizuho Maintains Buy on Arcus Biosciences, Lowers Price Target to $42-Report Released on 29 January 2024
Portfolio Pulse from Benzinga Newsdesk
Mizuho analyst Mara Goldstein has maintained a Buy rating on Arcus Biosciences (NYSE:RCUS) but reduced the price target from $51 to $42.

January 30, 2024 | 2:36 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Mizuho has maintained a Buy rating on Arcus Biosciences but lowered the price target from $51 to $42, indicating a positive outlook but with tempered expectations.
While the Buy rating suggests continued confidence in the company's prospects, the reduction in price target may reflect a reassessment of near-term growth expectations or market conditions. This could lead to mixed reactions in the short term, as investors appreciate the positive rating but also take into account the lower price target.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100